Depicting adoptive immunotherapy for prostate cancer in an animal model with magnetic resonance imaging

Magnetic Resonance in Medicine

Volumn 65, Issue 3, 2011, Pages 756-763

  Meier, Reinhard ^a   Golovko, Daniel ^b   Tavri, Sidhartha ^c   Henning, Tobias D ^a   Knopp, Christiane ^d   Piontek, Guido ^a   Rudelius, Martina ^a   Heinrich, Petra ^a   Wels, Winfried S ^d   Daldrup Link, Heike ^e  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^e STANFORD UNIVERSITY   (United States)

Author keywords

cell tracking; iron oxide nanoparticles; MR imaging; NK cells

Indexed keywords

ANTIGENS; CELL ADHESION; CELLS; DIAGNOSIS; GENETIC ENGINEERING; IRON OXIDES; MAGNETIC NANOPARTICLES; MAGNETIC RESONANCE IMAGING; NONINVASIVE MEDICAL PROCEDURES; TUMORS; UROLOGY;

CELL TRACKING; CONTRAST TO NOISE RATIO; EPITHELIAL CELL ADHESION MOLECULES; INTRAVENOUS INJECTIONS; IRON OXIDE NANOPARTICLE; MR IMAGING; NK CELLS; SUPERPARAMAGNETIC PARTICLES;

DISEASES;

EPITHELIAL CELL ADHESION MOLECULE; LYMPHOCYTE ANTIGEN RECEPTOR; NK 92 SINGLE CHAIN FRAGMENT VARIABLE MOC31 ZETA ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; CELL LABELING; CELL TRACKING; CONTROLLED STUDY; FLOW CYTOMETRY; GENETIC ENGINEERING; HISTOPATHOLOGY; IN VIVO STUDY; MALE; NATURAL KILLER CELL; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE CANCER; RAT; XENOGRAFT;

EID: 79951844228     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.22652     Document Type: Article

References (41)

1. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, Ward E, Wu XC, Eheman C, Anderson R, Ajani UA, Kohler B, Edwards BK,. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008; 100: 1672-1694.
2. Damber JE, Aus G,. Prostate cancer. Lancet 2008; 371: 1710-1721. (Pubitemid 351671887)
3. Moon C, Park JC, Chae YK, Yun JH, Kim S,. Current status of experimental therapeutics for prostate cancer. Cancer Lett 2008; 266: 116-134.
4. Tonn T, Seifried E,. Natural killer cells for the treatment of malignancies. Transfus Med Hemother 2006; 33: 144-149.
5. Muller T, Uherek C, Maki G, Chow KU, Schimpf A, Klingemann HG, Tonn T, Wels WS,. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother 2008; 57: 411-423. (Pubitemid 350295385)
6. Tavri S, Jha P, Meier R, Henning TD, Muller T, Hostetter D, Knopp C, Johansson M, Reinhart V, Boddington S, Sista A, Wels WS, Daldrup-Link HE,. Optical imaging of cellular immunotherapy against prostate cancer. Mol Imaging 2009; 8: 15-26.
7. Uherek C, Muller T, Tonn T, Uherek B, Klingemann HG, Wels WS,. Genetically modified natural killer cells specifically recognizing the tumor-associated antigens ErbB2/HER2 and EpCAM. Cancer Cell Int 2004; 4 (Suppl 1): S7.
8. Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG, Wels W,. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 2002; 100: 1265-1273. (Pubitemid 34864281)
9. Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H,. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 2008; 10: 625-632.
10. Tonn T, Becker S, Esser R, Schwabe D, Seifried E,. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 2001; 10: 535-544. (Pubitemid 32756192)
11. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ,. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-10951. (Pubitemid 41713363)
12. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA,. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006; 94: 128-135. (Pubitemid 43088552)
13. Daldrup-Link HE, Meier R, Rudelius M, Piontek G, Piert M, Metz S, Settles M, Uherek C, Wels W, Schlegel J, Rummeny EJ,. In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol 2005; 15: 4-13. (Pubitemid 40109763)
14. Oostendorp RA, Ghaffari S, Eaves CJ,. Kinetics of in vivo homing and recruitment into cycle of hematopoietic cells are organ-specific but CD44-independent. Bone Marrow Transplant 2000; 26: 559-566.
15. Adonai N, Nguyen KN, Walsh J, Iyer M, Toyokuni T, Phelps ME, McCarthy T, McCarthy DW, Gambhir SS,. Ex vivo cell labeling with 64Cu-pyruvaldehyde-bis(N4- methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography. Proc Natl Acad Sci USA 2002; 99: 3030-3035. (Pubitemid 34240580)
16. Daldrup-Link HE, Rudelius M, Metz S, Piontek G, Pichler B, Settles M, Heinzmann U, Schlegel J, Oostendorp RA, Rummeny EJ,. Cell tracking with gadophrin-2: a bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy. Eur J Nucl Med Mol Imaging 2004; 31: 1312-1321. (Pubitemid 39222496)
17. Daldrup-Link HE, Rudelius M, Piontek G, Metz S, Brauer R, Debus G, Corot C, Schlegel J, Link TM, Peschel C, Rummeny EJ, Oostendorp RA,. Migration of iron oxide-labeled human hematopoietic progenitor cells in a mouse model: in vivo monitoring with 1.5-T MR imaging equipment. Radiology 2005; 234: 197-205. (Pubitemid 39658386)
18. Bulte JW, Kraitchman DL,. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed 2004; 17: 484-499. (Pubitemid 39549426)
19. Daldrup-Link HE, Rudelius M, Oostendorp RA, Settles M, Piontek G, Metz S, Rosenbrock H, Keller U, Heinzmann U, Rummeny EJ, Schlegel J, Link TM,. Targeting of hematopoietic progenitor cells with MR contrast agents. Radiology 2003; 228: 760-767. (Pubitemid 37025487)
20. Suck G,. Novel approaches using natural killer cells in cancer therapy. Semin Cancer Biol 2006; 16: 412-418. (Pubitemid 44322046)
21. Di Paolo C, Willuda J, Kubetzko S, Lauffer I, Tschudi D, Waibel R, Pluckthun A, Stahel RA, Zangemeister-Wittke U,. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res 2003; 9: 2837-2848. (Pubitemid 36842130)
22. Poczatek RB, Myers RB, Manne U, Oelschlager DK, Weiss HL, Bostwick DG, Grizzle WE,. Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol 1999; 162: 1462-1466. (Pubitemid 29428619)
23. Evan GI, Lewis GK, Ramsay G, Bishop JM,. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol 1985; 5: 3610-3616. (Pubitemid 16233068)
24. Gong JH, Maki G, Klingemann HG,. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994; 8: 652-658. (Pubitemid 24133034)
25. Yan Y, Steinherz P, Klingemann HG, Dennig D, Childs BH, McGuirk J, O'Reilly RJ,. Antileukemia activity of a natural killer cell line against human leukemias. Clin Cancer Res 1998; 4: 2859-2868. (Pubitemid 28523516)
26. Jung CW,. Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 1995; 13: 675-691.
27. Wang YX, Hussain SM, Krestin GP,. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 2001; 11: 2319-2331. (Pubitemid 33041104)
28. Weissleder R,. Liver MR imaging with iron oxides: toward consensus and clinical practice. Radiology 1994; 193: 593-595. (Pubitemid 24366918)
29. Wolff SD, Balaban RS,. Assessing contrast on MR images. Radiology 1997; 202: 25-29. (Pubitemid 27024102)
30. Sedlmayr P, Rabinowich H, Elder EM, Ernstoff MS, Kirkwood JM, Herberman RB, Whiteside TL,. Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine-activated killer cells. J Immunother 1991; 10: 336-346.
31. Whiteside TL, Vujanovic NL, Herberman RB,. Natural killer cells and tumor therapy. Curr Top Microbiol Immunol 1998; 230: 221-244. (Pubitemid 28183725)
32. Chang E, Rosenberg SA,. Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy. J Immunother 2001; 24: 88-90. (Pubitemid 32101970)
33. Fujimiya Y, Suzuki Y, Katakura R, Ohno T,. Injury to autologous normal tissues and tumors mediated by lymphokine-activated killer (LAK) cells generated in vitro from peripheral blood mononuclear cells of glioblastoma patients. J Hematother 1999; 8: 29-37. (Pubitemid 29124988)
34. Kimoto Y, Tanaka T, Tanji Y, Fujiwara A, Taguchi T,. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies. Biotherapy 1994; 8: 41-50.
35. Klingemann HG, Wong E, Maki G,. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol Blood Marrow Transplant 1996; 2: 68-75. (Pubitemid 126488197)
36. Drexler HG, Matsuo Y,. Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma. Leukemia 2000; 14: 777-782. (Pubitemid 30235051)
37. Tam YK, Miyagawa B, Ho VC, Klingemann HG,. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J Hematother 1999; 8: 281-290. (Pubitemid 29310062)
38. Momburg F, Moldenhauer G, Hammerling GJ, Moller P,. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 1987; 47: 2883-2891. (Pubitemid 17113431)
39. Mosolits S, Nilsson B, Mellstedt H,. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Expert Rev Vaccines 2005; 4: 329-350. (Pubitemid 40978696)
40. Oberneder R, Weckermann D, Ebner B, Quadt C, Kirchinger P, Raum T, Locher M, Prang N, Baeuerle PA, Leo E,. A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. Eur J Cancer 2006; 42: 2530-2538. (Pubitemid 44442943)
41. Schwartzberg LS,. Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit Rev Oncol Hematol 2001; 40: 17-24. (Pubitemid 32923067)